Nureca Ltd

Nureca Limited has announced a trading window closure effective July 1, 2026, until 48 hours after the declaration of its Un-audited Financial Results for the first quarter ended June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. However, a waiver has been granted for Mr. Saurabh Goyal, Mr. Aryan Goyal, and Ms. Payal Goyal for inter se share transfers between July 1, 2026, and July 3, 2026, following prior intimation and pre-clearance under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Designated persons and their immediate relatives are restricted from trading during the closure period.

Nureca Ltd has received a disclosure regarding a proposed acquisition of equity shares through an inter-se transfer among its promoters. This transaction, involving members of the promoter group, is exempt from an open offer under SEBI regulations. The acquisition is scheduled to occur on or after July 01, 2026. The transfer involves approximately 20,59,928 shares from Mrs. Payal Goyal, representing 33.74% of the total share capital, to Mr. Aryan Goyal. The rationale cited is a family arrangement and internal re-alignment of promoter shareholding. The transaction is expected to be priced at INR 250.54 per share, based on the 60-day volume-weighted average market price.

Nureca Limited announced that its connected health platform, Dr Trust 360, has exceeded 2.4 million registered users. The company also launched Dr Trust Intelligence, an AI-powered analytics suite within the app. This suite offers personalized body-composition insights, automatic trend detection, and AI-guided recommendations, with health data stored and processed on servers in India. The Chairman and Managing Director, Saurabh Goyal, highlighted the trust Indian families place in the Dr Trust ecosystem and emphasized the platform's ability to provide actionable health insights. Dr Trust Intelligence is available as a premium subscription on Android and iOS.

Nureca Limited has been informed by certain members of its Promoter/Promoter Group about the execution of a Family Settlement Agreement (FSA) dated June 17, 2026. The company is not a party to this agreement. The FSA involves Mr. Saurabh Goyal, Ms. Smita Goyal, Mr. Aryan Goyal, and Ms. Payal Goyal, aiming for family settlement, succession planning, and reallocation of ownership interests and management responsibilities. Key terms include Mr. Aryan Goyal and Mrs. Payal Goyal transferring their shares to Mr. Saurabh Goyal, and Mr. Aryan Goyal stepping down as CEO and director. This is expected to further strengthen Mr. Saurabh Goyal's control, though it qualifies for exemption under SAST Regulations.

Nureca Limited has disclosed that Nectar Biopharma Private Limited, a member of the promoter group, disposed of 60,842 equity shares (0.63% of total shareholding) through an off-market transaction on June 9, 2026. While the disclosure was not strictly required as per recent SEBI circulars, the company made it as an abundant precaution. The transaction involved the sale of shares, with no value specified for the off-market deal.

Nureca Limited announced an inter-se transfer of 60,842 equity shares within its Promoter and Promoter Group. Nectar Biopharma Private Limited transferred these shares to Mr. Saurabh Goyal, a Promoter. The transaction, conducted off-market, resulted in no change to the aggregate shareholding of the Promoter and Promoter Group, which remains at 68.09%. This move represents an internal re-alignment of holdings among promoters.

Nureca Limited announced that its promoter, Mr. Saurabh Goyal, has acquired 1,43,70,880 equity shares through an off-market transaction on June 9, 2026. This acquisition increases his shareholding from 33.72% to 34.35%. The company is making this disclosure as a precautionary measure, even though it may not be strictly required under recent SEBI circulars.

Nureca Ltd issued a corrigendum to its board meeting outcome submitted on May 29, 2026, revising the approved incremental capital expenditure (capex) for plant and machinery from ₹100 crores to ₹128 crores. This investment targets the manufacturing of additional medical devices, healthcare consumables, and hygiene products at the existing company-owned industrial land in Sundran, Dera Bassi, Punjab. The board also reaffirmed its approval for purchasing additional land for future expansion. All other contents of the original board meeting outcome remain unchanged.

Nureca Ltd's board re-appointed M/s MGSG and Associates as Internal Auditor for FY 26-27. They approved the FY26 audited financial results with an unmodified opinion. Mr. Chander Kant was appointed as CFO and KMP effective June 27, 2026. The board approved the re-appointment of Mr. Aryan Goyal as Whole Time Director & CEO and Mr. Saurabh Goyal as Managing Director, subject to member approval. Ms. Smita Goyal was appointed as an Additional Director (Whole Time Director). The 10th AGM will be held on July 28, 2026, via video conferencing. The board also approved incremental capex of up to ₹100 crores for plant and machinery and the purchase of additional land for future expansion. Mr. Naresh Gupta resigned as CFO.

Nureca Limited has announced a change in its Chief Financial Officer (CFO). Mr. Naresh Gupta resigned as CFO effective June 26, 2026, and Mr. Chander Kant will assume the role from June 27, 2026. Consequently, Mr. Chander Kant is additionally authorized to determine materiality of events and make disclosures to stock exchanges. The authorized personnel for these disclosures now include Mr. Saurabh Goyal, Mr. Aryan Goyal, Ms. Nishu Kansal, and Mr. Chander Kant. The single point of contact remains cs@nureca.com.